1. Home
  2. IMUX vs GLU Comparison

IMUX vs GLU Comparison

Compare IMUX & GLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • GLU
  • Stock Information
  • Founded
  • IMUX 2016
  • GLU 2004
  • Country
  • IMUX United States
  • GLU United States
  • Employees
  • IMUX N/A
  • GLU N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • GLU Finance/Investors Services
  • Sector
  • IMUX Health Care
  • GLU Finance
  • Exchange
  • IMUX Nasdaq
  • GLU Nasdaq
  • Market Cap
  • IMUX 92.2M
  • GLU 108.3M
  • IPO Year
  • IMUX N/A
  • GLU N/A
  • Fundamental
  • Price
  • IMUX $0.76
  • GLU $18.07
  • Analyst Decision
  • IMUX Strong Buy
  • GLU
  • Analyst Count
  • IMUX 5
  • GLU 0
  • Target Price
  • IMUX $6.00
  • GLU N/A
  • AVG Volume (30 Days)
  • IMUX 1.3M
  • GLU 12.4K
  • Earning Date
  • IMUX 11-13-2025
  • GLU 01-01-0001
  • Dividend Yield
  • IMUX N/A
  • GLU 8.60%
  • EPS Growth
  • IMUX N/A
  • GLU N/A
  • EPS
  • IMUX N/A
  • GLU 0.62
  • Revenue
  • IMUX N/A
  • GLU N/A
  • Revenue This Year
  • IMUX N/A
  • GLU N/A
  • Revenue Next Year
  • IMUX N/A
  • GLU N/A
  • P/E Ratio
  • IMUX N/A
  • GLU $22.50
  • Revenue Growth
  • IMUX N/A
  • GLU N/A
  • 52 Week Low
  • IMUX $0.56
  • GLU $11.61
  • 52 Week High
  • IMUX $1.42
  • GLU $15.40
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 47.49
  • GLU 46.79
  • Support Level
  • IMUX $0.67
  • GLU $17.95
  • Resistance Level
  • IMUX $0.79
  • GLU $18.35
  • Average True Range (ATR)
  • IMUX 0.05
  • GLU 0.25
  • MACD
  • IMUX 0.00
  • GLU -0.01
  • Stochastic Oscillator
  • IMUX 64.28
  • GLU 31.38

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About GLU Gabelli Global Utility of Beneficial Ownership

Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.

Share on Social Networks: